Amanta Healthcare Ltd

Transaction overview

• Off-market inter-se transfer between promoter-group members on Sep 28, 2026.

Disclosing party

• Seller: Pravinchandra Dhanjibhai Mehta, Member of Promoter Group.

Target company

• Target Company: Amanta Healthcare Limited.

Pre-Transaction Holding

• Pre-disposal holding: 19,82,763 shares, 5.11%.

Transaction details

• Disposed of 1,50,400 equity shares at Rs 190 per share, 0.39% VR.

Post-Transaction Holding

• Post-disposal holding: 18,32,363 shares, 4.72%.

Share capital context

• Equity share capital before/after: 3,88,29,351 shares; diluted: 3,88,29,351.

Mode of transfer

• Mode: Off-market inter-se transfer within Promoter Group.

Date of transaction

• Transaction date: September 28, 2026.

Regulatory insider trading disclosures

• Filing date: 30 September 2026.
• Form C disclosures from two promoter group members: Pravinchandra Mehta and Kirit Desai.
• Disclosures relate to off-market equity share transactions.
• Exchanges requested to record the disclosures.

AGM Details

• Date/time/mode: 16 Sep 2026, 12:00 IST, VC/OAVM.
• Venue deemed at Registered Office via VC/OAVM.
• Remote e-voting: 13–15 Sep 2026; AGM voting available.
• Cut-off for voting eligibility: 9 Sep 2026.
• Annual Report dispatched: 24 Aug 2026.
• Record/entitlement date: 14 Aug 2026.

Resolutions and outcomes

• Resolution 1: Adopt Audited Financial Statements for FY2025-26; Ordinary; Passed 100% in favour, 1 against.
• Resolution 2: Re-appoint Shri Nimesh P Patel; Ordinary; Passed 99.93% in favour, 0.07% against.
• Resolution 3: Appoint Secretarial Auditor for 5 consecutive years; Ordinary; Passed 100% in favour, 1 against.
• Resolution 4: Ratify cost auditor remuneration for FY2026-27; Ordinary; Passed 100% in favour, 120 against.
• Resolution 5: Approve remuneration revision for Shri Bhavesh Girishbhai Patel; Special; Passed 100% in favour, 239 against.

Auditor/Appointments

• Secretarial Auditor appointed for 5 consecutive years.
• Cost Auditor remuneration ratified for FY2026-27.

Director/Management Changes

• Director Shri Nimesh P Patel retires by rotation; re-appointed.

Director appointment

• Type: Appointment of Mr. Nimesh P Patel as Director retire by rotation.
• Name/Designation: Mr. Nimesh P Patel, Non-Executive, Non-Independent Director.
• Effective date: 16 September 2026; Term: retire by rotation.
• Tenure: On board since 14 December 2020.
• Profile: Wharton School graduate; 5+ years in pharmaceutical industry.
• Related party: Cousin of Chairman and MD Bhavesh Girishbhai Patel.

Secretarial Auditor appointment

• Type: Appointment of Secretarial Auditor.
• Name/firm: M/s Kashyap R. Mehta & Partners, Practising Company Secretaries.
• Term: 5 consecutive years from 2026-27 to 2030-31.
• Reason: Appointed as Secretarial Auditor; subject to AGM approval.
• Profile: Ahmedabad-based firm with four decades in governance and SEBI-law expertise.
• Relationship: Not Applicable.

AGM Details

• Date/time: Sep 16, 2026 at 12:00 P.M. IST; mode: VC/OAVM.
• Meeting commenced 12:09 P.M. and concluded 12:48 P.M. (incl. e-voting).

Resolutions Presented

• Adoption of financial statements for FY2025-26 – Ordinary.
• Appointment of Nimesh P Patel as director by rotation – Ordinary.
• Appointment of Kashyap R. Mehta & Partners as Secretarial Auditors for five years – Ordinary.
• Ratification of remuneration of Cost Auditor for FY2026-27 – Ordinary.
• Revision in remuneration of MD Bhavesh Girishbhai Patel – Special.

Voting and Attendance

• 34 members attended; voting via CDSL; results to be declared on company website.

SteriPort line commissioning

• Commencement of production at the new SteriPort facility on the Kheda campus.
• Facility is brownfield, with higher automation and reduced human interference.
• Two-port SteriPort system provides leakproof IV administration.
• Designed for potent drugs, especially oncology and intensive care applications.
• Aims to expand EBITDA margin via improved operational efficiency.

AGM notice and annual report access

• 31st AGM scheduled for 16 September 2026 at 12:00 IST via VC/OAVM.
• Integrated Annual Report for FY2025-26 and AGM notice accessible online.
• Weblink path: https://www.amanta.co.in/annual-report.
• Shareholders without registered email addresses by Aug 14, 2026 advised to update details.
• SEBI LODR-based KYC updation and dematerialisation of physical securities highlighted.
• RTA helpdesk link provided for electronic service requests.
• Physical-holding payments will be through electronic mode only from Apr 1, 2024.
• Letter dated Aug 24, 2026 informing non-registered email holders.
• Company Secretary and Compliance Officer: Nikhita Dinodia.

Financials

• Revenue from operations: ₹28,767.67 Lakhs; up 5% YoY.
• EBITDA: ₹6,322.92 Lakhs; margin 22%.
• PAT: ₹1,487.52 Lakhs; margin 5%.
• EPS: ₹4.33 (basic and diluted).
• ROE 8.94%; ROCE 11.11%.
• Debt-to-Equity 0.99x; DSCR 1.01x.

Debt & capital structure

• Total borrowings: ₹24,444.34 Lakhs; equity: ₹3,882.94 Lakhs.
• IPO proceeds raised: ₹126 Crores; anchor allocations ₹37.80 Crores.
• Debt-to-Equity declined from 3x+ in FY23 to 0.99x in FY26.

Capex & capacity expansion

• SteriPort capacity to ~12 crore bottles/year (from 6.6).
• SVP capacity to ~31.7 crore units by FY27.
• FY26 capex: ₹130 Crores for SteriPort; ₹25 Crores for SVP.
• 8 MW captive solar plant commissioned; ₹9 Crores annual savings from FY27.

IPO proceeds & usage

• IPO proceeds: ₹126 Crores; used for capex and general corporate purposes.
• Unutilised IPO proceeds: ₹5,246.75 Lakhs as of 31 Mar 2026.
• Monitoring of utilisation by CRISIL; annual quarterly reviews.

Geography & product footprint

• Domestic revenue ₹17,349.76 Lakhs; export ₹11,069.63 Lakhs (FY26).
• Export markets: 20 countries; 47 products registered across 120 jurisdictions.
• Six therapeutic segments; LVP and SVP capabilities with ISBM/ABFS.

ESG, sustainability & CSR

• ISO 14001:2015; WHO-GMP; captive solar plant reduces carbon footprint.
• CSR spend ₹28.72 Lakhs; CSR obligation ₹14.99 Lakhs; no shortfall.
• ESG initiatives include greener packaging, energy efficiency, and water reuse.

Governance & risk

• Board: 6 directors; 3 independent; 1 woman. Audit Committee reconstituted.
• Secretarial Auditor: Kashyap R. Mehta & Partners; 5-year term subject to AGM approval.
• Statutory Auditor: PwC; 5-year term; unmodified opinion.
• Dividend: no dividend declared for FY26.

Key business risks

• Foreign exchange risk in 20 export markets; hedging limited.
• Single manufacturing site; potential supply/disruption risk.
• Pricing pressure in competitive segments; shift to differentiated products.